Free Trial
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$229.23
+2.9%		$246.62
$186.05
▼
$282.15
$14.30B0.38969,992 shs815,738 shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$59.86
+1.4%		$56.26
$33.76
▼
$61.14
$14.83B0.472.22 million shs2.67 million shs
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
$14.49
$14.42
$5.51
▼
$14.50
$4.55B0.482.62 million shs5.29 million shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$17.59
+2.4%		$15.55
$12.07
▼
$29.23
$14.07B-1.517.54 million shs5.75 million shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.00%+0.60%-12.25%-15.24%+9.09%
Exelixis, Inc. stock logo
EXEL
Exelixis
0.00%+2.52%+4.23%+5.95%+54.92%
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
0.00%0.00%0.00%0.00%+75.42%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
0.00%+5.01%+3.47%+15.34%-24.64%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$229.23
+2.9%		$246.62
$186.05
▼
$282.15
$14.30B0.38969,992 shs815,738 shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$59.86
+1.4%		$56.26
$33.76
▼
$61.14
$14.83B0.472.22 million shs2.67 million shs
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
$14.49
$14.42
$5.51
▼
$14.50
$4.55B0.482.62 million shs5.29 million shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$17.59
+2.4%		$15.55
$12.07
▼
$29.23
$14.07B-1.517.54 million shs5.75 million shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.00%+0.60%-12.25%-15.24%+9.09%
Exelixis, Inc. stock logo
EXEL
Exelixis
0.00%+2.52%+4.23%+5.95%+54.92%
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
0.00%0.00%0.00%0.00%+75.42%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
0.00%+5.01%+3.47%+15.34%-24.64%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.00
Buy$313.2136.64% Upside
Exelixis, Inc. stock logo
EXEL
Exelixis
2.35
Hold$50.79-15.16% Downside
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
2.00
Hold$14.641.05% Upside
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.53
Moderate Buy$28.6162.64% Upside

Current Analyst Ratings Breakdown

Latest FOLD, EXEL, ASND, and SMMT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/9/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetSector Perform$51.00
10/8/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeBuy (A-) ➝ Buy (A)
10/8/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetSector Perform$46.00 ➝ $45.00
10/7/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetHold$52.00 ➝ $54.00
10/5/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Perform
10/1/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$18.00 ➝ $20.00
9/30/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
9/29/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetBuy$41.00
9/29/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperform
9/29/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$30.00
9/25/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$40.00 ➝ $43.00
(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M17.55N/AN/A($2.97) per share-77.18
Exelixis, Inc. stock logo
EXEL
Exelixis
$2.32B6.39$3.03 per share19.77$8.06 per share7.43
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
$634.21M7.17$0.06 per share234.67$0.87 per share16.66
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/A$0.85 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$12.8917.7825.61N/A70.99%32.54%7.71%11/11/2026 (Estimated)
Exelixis, Inc. stock logo
EXEL
Exelixis
$782.57M$3.1818.8216.131.7835.33%42.17%31.76%11/3/2026 (Estimated)
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
-$27.11M-$0.08N/A18.82N/A-4.27%4.15%1.09%N/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$1.08B-$1.12N/AN/AN/AN/A-168.94%-141.92%10/19/2026 (Estimated)

Latest FOLD, EXEL, ASND, and SMMT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/3/2026Q3 2026
Exelixis, Inc. stock logo
EXEL
Exelixis
$0.8780N/AN/AN/A$646.95 millionN/A
10/19/2026Q3 2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.28N/AN/AN/A$0.07 millionN/A
8/14/2026Q2 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$1.71$1.0270-$0.6830$3.23$376.75 million$387.22 million
8/5/2026Q2 2026
Exelixis, Inc. stock logo
EXEL
Exelixis
$0.8530$0.91+$0.0570$0.8438$636.40 million$628.69 million
7/23/2026Q2 2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.2744-$0.28-$0.0056-$0.28$0.11 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
Exelixis, Inc. stock logo
EXEL
Exelixis
N/AN/AN/AN/AN/A
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
N/AN/AN/AN/AN/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.27
2.99
2.32
Exelixis, Inc. stock logo
EXEL
Exelixis
N/A
3.46
3.38
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
1.43
2.84
1.88
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/A
6.96
6.96

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
Exelixis, Inc. stock logo
EXEL
Exelixis
85.27%
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
N/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
4.61%

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
Exelixis, Inc. stock logo
EXEL
Exelixis
2.60%
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
2.20%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
83.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
Exelixis, Inc. stock logo
EXEL
Exelixis
1,077247.78 million241.34 millionOptionable
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
480314.00 million307.09 millionOptionable
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
265799.73 million131.96 millionOptionable

Recent News About These Companies

Summit Therapeutics (NASDAQ:SMMT) Stock Jumps 3.6% - What's Next?
October 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-summit-therapeutics-nasdaq-smmt-stock-jumps-36-whats-next-2026-10-07/
SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos
October 5, 2026  |  zacks.comhttps://www.zacks.com/stock/news/3000206/smmt-inks-deal-with-azn-daiichi-to-study-ivonescimab-datroway-combos?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-3000206
Summit Therapeutics (SMMT) Is Up 7.3% After $2 Billion AstraZeneca Partnership and Trial Collaboration
October 2, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/summit-therapeutics-smmt-7-3-230615020.html
Daiichi Sankyo, AstraZenca, Summit Partner To Evaluate Datroway Plus Ivonescimab
October 2, 2026  |  rttnews.comhttps://www.rttnews.com/3696045/daiichi-sankyo-astrazenca-summit-partner-to-evaluate-datroway-plus-ivonescimab.aspx
Summit Therapeutics (NASDAQ:SMMT) Shares Climb 7.1% - Here's What Happened
October 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31078640
Summit agrees to $2 billion AstraZeneca equity investment
October 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31078180
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
October 2, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261001197318/en/summit-therapeutics-announces-clinical-trial-collaboration-with-astrazeneca-and-daiichi-sankyo-to-evaluate-ivonescimab-in-combination-with-trop2-directed-adc-datroway/
Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types
October 2, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261001131464/en/daiichi-sankyo-and-astrazeneca-enter-into-clinical-trial-collaboration-with-summit-therapeutics-to-evaluate-datroway%c2%ae-in-combination-with-ivonescimab-across-multiple-tumor-types/
What Does Summit Therapeutics (SMMT) Gain From This $2 Billion Cancer Partnership?
October 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/does-summit-therapeutics-smmt-gain-220553806.html
AstraZeneca’s $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets
September 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/astrazeneca-2-billion-vote-confidence-151701810.html
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT), Argenx Se (ARGX) and Obsidian Therapeutics (OBX)
September 30, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/4883679/analysts-offer-insights-on-healthcare-companies-summit-therapeutics-smmt-argenx-se-argx-and-obsidian-therapeutics-obx/
Summit Therapeutics (NASDAQ:SMMT) Stock Price Up 7.1% - What's Next?
September 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-summit-therapeutics-nasdaq-smmt-stock-price-up-71-whats-next-2026-09-30/
AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets
September 30, 2026  |  247wallst.comhttps://247wallst.com/investing/2026/09/30/astrazenecas-2-billion-vote-of-confidence-leaves-summit-therapeutics-trading-well-below-street-targets/?utm_source=snapi
AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says
September 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/astrazeneca-apos-2-billion-investment-190315458.html
Summit Therapeutics PLC ADR (SMMT)
September 30, 2026  |  ca.investing.comhttps://ca.investing.com/equities/summit-therapeutics-plc-news
Summit Shares Jump on $2B Strategic Investment From AstraZeneca
September 29, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2997738/summit-shares-jump-on-2b-strategic-investment-from-astrazeneca?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2997738
Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up - Still a Buy?
September 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-summit-therapeutics-nasdaq-smmt-shares-gap-up-still-a-buy-2026-09-29/
Summit Therapeutics jumps 20% after AstraZeneca's $2 billion bet: what it signals
September 29, 2026  |  invezz.comI
AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal
September 29, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1099267?snapi
AstraZeneca Invests $2 Billion In Summit, Expands Cancer Drug Collaboration; Stock Up
September 28, 2026  |  rttnews.comhttps://www.rttnews.com/3694521/astrazeneca-invests-2-billion-in-summit-expands-cancer-drug-collaboration-stock-up.aspx
Summit Therapeutics rises after AstraZeneca commits $2B investment
September 28, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/summit-therapeutics-rises-after-astrazeneca-commits-2b-investment/ar-AA2d9pUc

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
Stacks of coins rising on a desk beside a computer with an upward stock chart, with a blurred city skyline behind.
3 Dividend Kings to Buy While They’re Still Beaten Down
By Thomas Hughes | September 14, 2026
Shopping bags sit on a polished marble floor inside an upscale retail store or shopping mall.
3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
By Nathan Reiff | September 16, 2026
Computer monitor with a red plunging chart arrow on a desk, symbolizing software stocks selloff amid AI fears.
MarketBeat's Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
By Thomas Hughes | September 15, 2026
Illuminated Apple logo on a glass wall inside a store, with a city skyline visible at sunset.
Apple Stock Surges After Its Biggest Product Launch in Years—Can It Last?
By Sam Quirke | September 16, 2026
Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$229.23 +6.54 (+2.94%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$229.14 -0.09 (-0.04%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Exelixis stock logo

Exelixis NASDAQ:EXEL

$59.86 +0.84 (+1.42%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$60.06 +0.20 (+0.33%)
As of 10/9/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Amicus Therapeutics stock logo

Amicus Therapeutics NASDAQ:FOLD

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Summit Therapeutics stock logo

Summit Therapeutics NASDAQ:SMMT

$17.59 +0.42 (+2.45%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$17.60 +0.00 (+0.03%)
As of 10/9/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas